Bioamber (NYSE:BIOA) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Friday.

Several other equities research analysts have also issued reports on the company. Cowen reaffirmed a “hold” rating and set a $1.00 target price on shares of Bioamber in a research report on Friday, November 10th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Bioamber in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. Bioamber presently has a consensus rating of “Hold” and an average target price of $6.50.

Shares of Bioamber (BIOA) traded down $0.02 during trading on Friday, hitting $0.42. The stock had a trading volume of 938,709 shares, compared to its average volume of 948,388. Bioamber has a 1 year low of $0.32 and a 1 year high of $6.24. The company has a quick ratio of 0.75, a current ratio of 1.08 and a debt-to-equity ratio of 0.24.

A number of institutional investors and hedge funds have recently made changes to their positions in BIOA. Robecosam AG increased its holdings in Bioamber by 82.9% in the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock worth $741,000 after acquiring an additional 670,000 shares during the last quarter. TD Asset Management Inc. purchased a new stake in Bioamber in the 2nd quarter worth about $977,000. Bank of New York Mellon Corp increased its holdings in Bioamber by 336.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 41,701 shares during the last quarter. Vanguard Group Inc. increased its holdings in Bioamber by 9.9% in the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock worth $780,000 after acquiring an additional 27,278 shares during the last quarter. Finally, FMR LLC increased its holdings in Bioamber by 1.9% in the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock worth $3,495,000 after acquiring an additional 25,000 shares during the last quarter. 29.97% of the stock is owned by institutional investors.

WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/01/bioamber-bioa-lowered-to-strong-sell-at-valuengine.html.

Bioamber Company Profile

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with MarketBeat.com's FREE daily email newsletter.